Status:
NOT_YET_RECRUITING
Bumetanide vs. Furosemide in Cirrhosis
Lead Sponsor:
Stacy Johnson
Conditions:
Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associat...
Eligibility Criteria
Inclusion
- History of liver cirrhosis
- Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital
Exclusion
- Allergy to bumetanide or furosemide
- Contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension)
- Incarcerated or in custody of law enforcement
- Diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload)
- Inpatient admission not anticipated
- Not admitted to an inpatient hospital bed following initial evaluation in the emergency department
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06941415
Start Date
March 1 2026
End Date
March 31 2029
Last Update
October 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah Hospital
Salt Lake City, Utah, United States, 84132